is there a reason people titrate this over more weeks than the others
#cagrilintide 2025-07-13
Sunday37 messages9 participantstimes are UTC
Highlights from this day
- ms_ms_mira — two VendorInvestigate results on the same BCH lot came back 96.8 and 99, closer than i expected noticed something around week 6 on monotherapy, well after i had given… 19:45
- bpc_sceptic — anyone stopped the GLP-1 and kept only this 20:04
- week_three_wall — amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist 21:02
- lyophile_liv — does amylin do something about fullness that the GLP-1 doesnt 21:06
how do people separate which of the two is doing what in a combination
separate days
sorry to jump in i keep the two on separate days so if something goes wrong i have a chance of knowing which
the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing
amylin not glp-1
did anyone find monotherapy underwhelming
fullness rather than nausea
combination for me
if youre used to GLP-1 titration steps this feels absurdly cautious and i still do it that way
REDEFINE is the trial
site-rotation-map.png
1000 × 700 · 459 KB · not retained in the public archive
unrelated but is the nausea profile genuinely different or am i imagining it
for the archive REDEFINE is the phase 3 programme, most of what gets quoted casually in here is earlier work
the combination is the thing with trial data behind it, monotherapy in here is mostly us guessing, from memory
nobody should copy my schedule, im describing it because people asked what a slow ramp looks like
thats the phase 3 one
whats the recon people use, 2 in 1.5ml
combination GI was worse than either alone for me, which is not what i had read anywhere
amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist
does the fullness effect fade the way appetite suppression does
€72 for a 15 vial and it lasts me longer than the GLP-1 does at my doses, anyway
the reason nausea reads differently is timing, mine arrived on the second day rather than the first
genuine question added it to an existing cagrilintide dose rather than starting both, which made attribution possible, not advice obviously
underwhelming honestly
🙏8📈9🧪7
two VendorInvestigate results on the same BCH lot came back 96.8 and 99, closer than i expected
noticed something around week 6 on monotherapy, well after i had given up expecting to
titrating dead slow
anyone stopped the GLP-1 and kept only this
📉9🔥15🧊9
right so back after 21 months, is monotherapy still a minority thing here
the fullness effect hasnt faded over 21 months, unlike my semaglutide appetite curve
held mine a while
[edited]is 2.4 the number for this too or am i confusing compounds
dropped the GLP-1 and stayed on this alone for 8 months, appetite held but weight barely moved
CagriSema is cagrilintide with semaglutide and REDEFINE is the trial programme around it
amylin is about slowed gastric emptying and satiety signalling, thats the short version and im no pharmacologist
🧊7🎉8
genuine question is the weekly schedule the same here
does amylin do something about fullness that the GLP-1 doesnt
🤝1🙏5
its an amylin analogue, different receptor family, so treating it as another GLP-1 is the first mistake, someone check my working
monotherapy here
ok so i titrated over twice as many weeks as i did on semaglutide and that was right for me
slower than the others